Human non-small-cell lung cancer (NSCLC) is considered to be a chemotherapy-refractory malignancy. The underlying mechanisms remain rather obscure. The multidrug resistanceassociated protein (MRP), mediating a multidrug resistance (MDR) phenotype, has been reported to be overexpressed in several dru
Modulation of cell cycle-related protein expression by sodium butyrate in human non-small cell lung cancer cell lines
β Scribed by Cinzia Pellizzaro; Danila Coradini; Antonella Daniotti; Gabriella Abolafio; Maria Grazia Daidone
- Publisher
- John Wiley and Sons
- Year
- 2001
- Tongue
- French
- Weight
- 79 KB
- Volume
- 91
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Activation of protein kinase C- (PKC) and Fos/Jun-dependent signal transduction pathways are thought to be major effects of oncogene action in different tumor systems including human non-small-cell lung carcinoma (NSCLC). We have previously shown that the phorbol ester analogue phorbol-myristate-ace
Non-small-cell lung cancer (NSCLC) cells are characterised by resistance to the toxic impact of antineoplastic drugs both in vivo and in vitro. The lung resistance-related protein (LRP), identical with the human major vault protein, is over-expressed in a variety of tumour cells characterised by int
To generate non-small cell lung cancer (NSCLC)-reactive lymphocytes, we transfected an HLA-A2-expressing human NSCLC line (1355) with the cDNA encoding the lymphocyte co-stimulatory molecule CD80. Following selection in G418, 1355.7 demonstrated stable cell-surface expression of CD80. Allogeneic mix
Cdk4-mediated phosphorylation of Rb protein is inhibited by pl6, a product of a possible tumor suppressor gene. We examined the expression of p16 and Rb protein by means of immunohistochemistry in 61 non-small cell lung cancers and have demonstrated an inverse relationship between the expression of
An in vitro model that might be relevant to cancer cell chemoresistance in vivo was generated by exposing the human lung carcinoma clonal cell line DLKP-SQ to 10 sequential pulses of pharmacologically attainable doses of doxorubicin. The resistant variant, DLKP-SQ/10p, was found to be cross-resistan